- $137.40m
- $131.64m
Brief: Enlivex Awarded Grant To Support Clinical Development Of Allocetra In Sepsis Patients
Brief: Enlivex Appoints Dr. Roger Pomerantz To Board As Vice Chairman
Brief: Enlivex Announces Issuance Of Two U.S. Patents Covering Methods Of Treating Sepsis With Allocetra
Brief: Enlivex Announces Issuance Of Israeli Patent Covering Allocetra Derived From Pooled Donor Cells
Brief: Enlivex Receives Regulatory Authorization To Expand Its Phase IIb Trial Evaluating Allocetra In Severe And Critical COVID-19 Patients Into Greece
Enlivex up after Greece allows sepsis treatment trial
Brief: Enlivex Receives Regulatory Authorization To Expand Its Phase II Sepsis Trial Into Greece
Brief: Enlivex Receives Notice Of Allowance For U.S. Patent Application Covering Treatment Of Sepsis Patients With Allocetra
Brief: Enlivex Therapeutics Ltd Says Qtrly Net Loss $3.4 Mln
Brief: Spanish Regulator Grants Enlivex Authorization To Expand Its Phase IIB Trial Evaluating Allocetra
Brief: Spanish Regulator Grants Enlivex Authorization To Expand Its Sepsis Phase II Into Spain
Brief: Enlivex Announces The Peer-Reviewed Publication In Frontiers In Immunology Of Clinical Data From Phase Ib Trial Evaluating Allocetra In Patients With Sepsis
Brief: Enlivex Doses First Patient In Placebo-Controlled Phase IIb Trial Testing Allocetra In Critical COVID-19 Patients With ARDS
NASDAQ RESUMED AT 09:45 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:40 AM
Enlivex soars after Israel allows COVID-19 therapy trial
Brief: Enlivex Says Israeli Ministry Of Health Authorizes Initiation Of Phase IIb Clinical Trial Evaluating Allocetra In Severe COVID-19 Patients
Brief: Enlivex Announces Q2 Results
Brief: Enlivex Therapeutics Reports Quarterly Loss Per Share $0.17